{"schema_version":"secwatch.filing_event.v1","accession":"0001140361-23-052102","form_type":"8-K","ticker":"ADMA","cik":"0001368514","company_name":"ADMA BIOLOGICS, INC.","filed_at":"2023-11-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:28.772911+00:00","generated_at":"2026-06-08T08:57:30.400878+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"ADMA Biologics Q3 2023: first-time net income $2.6M, revenue $67.3M (+64% YoY), raises FY guidance","bullets":["Total revenues $67.3M, up 64% YoY; first-time positive GAAP net income of $2.6M (vs $14.9M loss YoY).","Adjusted EBITDA grew to $12.7M, up 98% QoQ; first-time positive operating cash flow of $12.0M; cash balance $74.2M.","Gross margin improved to 36.6% from 23.5% YoY; net leverage ratio improved to 1.6x.","FY2023 revenue guidance raised to >$250M; FY2024 >$290M; FY2025 >$335M (from $240M, $275M, $320M previously).","Targets consolidated gross margin 40-50% and net income margin 20-30% in 2024-2025; ongoing strategic review."],"urls":{"canonical":"https://secwatch.observer/filing/0001140361-23-052102","json":"https://secwatch.observer/filing/0001140361-23-052102.json","markdown":"https://secwatch.observer/filing/0001140361-23-052102.md","text":"https://secwatch.observer/filing/0001140361-23-052102.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1368514/000114036123052102/0001140361-23-052102-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1368514/000114036123052102/ef20014134_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-08T08:57:30.400878+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"6ab1ad8536ca5cfbbd096047b47e1c24b74fa9d8","claim":"ADMA BIOLOGICS, INC. reported three months ended September 30, 2023 results: revenue $67.3 Million, net income $2.6 Million. Guidance raised.","evidence_excerpt":"ADMA Biologics Announces Third Quarter 2023 Financial Results and Provides Business Update 3Q2023 Total Revenues of $67.3 Million, a 64% Y-o-Y Increase First-Time Positive GAAP Net Income of $2.6 Million","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1368514/000114036123052102/0001140361-23-052102-index.htm","confidence":1.0,"family_label":"Earnings Releases","details":[{"label":"Period","value":"three months ended September 30, 2023"},{"label":"Revenue","value":"$67.3 Million"},{"label":"Net income","value":"$2.6 Million"},{"label":"Guidance","value":"raised"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}